Results 191 to 200 of about 2,115,420 (216)

The American College of Rheumatology Updated Recommended Methods for Development of Disease Classification and Response Criteria

open access: yesArthritis &Rheumatology, EarlyView.
Disease classification criteria and response criteria are important tools in the conduct of observational studies and clinical trials for rheumatic diseases. This paper updates methodologic guidance for classification and response criteria funded, developed and/or endorsed by the American College of Rheumatology (ACR), incorporating contemporary ...
Sindhu R. Johnson   +4 more
wiley   +1 more source

A Pragmatic Trial of a Shared Decision‐Making Intervention to Improve Medication Adherence and Outcomes in Systemic Lupus Erythematosus: The HCQ‐SAFE Study

open access: yesArthritis &Rheumatology, EarlyView.
Objective Hydroxychloroquine (HCQ) nonadherence in systemic lupus erythematosus (SLE) stemming from decision complexities can be improved with shared decision‐making (SDM) tools clarifying benefits and harms. This study aimed to develop and evaluate HCQ‐SAFE, a pictogram‐based SDM tool during SLE visits.
Caroline Packee   +8 more
wiley   +1 more source

Fine Particulate Matter Constituents, Ozone, and Systemic Lupus Erythematosus: A Large General‐Population Cohort Analysis With Extended Quantile g‐Computation

open access: yesArthritis &Rheumatology, EarlyView.
Objective The aim of this study was to investigate whether exposure to mixture of individual fine particulate matter (PM2.5) chemical constituents is associated with incident systemic lupus erythematosus (SLE) and if ozone modifies this association and/or is associated with SLE onset.
Naizhuo Zhao   +9 more
wiley   +1 more source

Nonmelanoma Skin Cancer Risk With JAK Inhibitors Compared to Interleukin‐6 Receptor Inhibitors in Rheumatoid Arthritis: Results From a National Cohort Study

open access: yesArthritis &Rheumatology, EarlyView.
Objective Nonmelanoma skin cancer (NMSC) is one of the most common malignancies in rheumatoid arthritis (RA). This analysis assessed NMSC risk with JAK inhibitors (JAKi) compared to interleukin‐6 receptor inhibitors (IL‐6Ri). Methods This study used data from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis linked to the
Zixing Tian   +8 more
wiley   +1 more source

Outcomes in progressive pulmonary fibrosis in systemic autoimmune rheumatic diseases: real‐world data from the ILD‐PRO Registry

open access: yesArthritis &Rheumatology, Accepted Article.
Objective We evaluated baseline characteristics, treatment patterns, and outcomes in patients with systemic autoimmune rheumatic disease‐associated progressive pulmonary fibrosis (SARD‐PPF) and evaluated whether outcomes differed by SARD subtype. Methods The ILD‐PRO Registry is a prospective multicenter US registry of patients with PPF.
Sonali J Bracken   +7 more
wiley   +1 more source

Risk of Cancer According to Duration of Targeted Therapy Exposure in Spondyloarthritis: A Nationwide Cohort Study From the French Health Insurance Database

open access: yesArthritis &Rheumatology, EarlyView.
Objective To assess the association between duration of targeted therapy exposure and cancer risk in patients with spondyloarthritis (SpA), including those with psoriatic arthritis, axial SpA, and other subtypes. Methods This nationwide cohort study used the French health insurance database to identify adults with SpA initiating a targeted therapy ...
Karine Tankovic   +7 more
wiley   +1 more source
Some of the next articles are maybe not open access.

Related searches:

Health insurance status and cancer stage at diagnosis and survival in the United States

Ca-A Cancer Journal for Clinicians, 2022
Leticia Nogueira, Xuesong Han
exaly  

Older adult participation in cancer clinical trials: A systematic review of barriers and interventions

Ca-A Cancer Journal for Clinicians, 2021
William P Tew   +2 more
exaly  

Internet and private insurance participation

International Journal of Finance and Economics, 2022
Tingting Zhang, Wenquan Li, Zhifeng Liu
exaly  

Home - About - Disclaimer - Privacy